Physician
Sierra Hematology and Oncology Medical Centers
Sierra Hematology and Oncology Medical Centers was paid $3.40M by Medicaid between Jan 2018 and Nov 2024, across 65 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoSIERRA HEMATOLOGY AND ONCOLOGY MEDICAL CENTERS
CARMICHAEL, CA 95608
CARMICHAEL, CA 95608
33aNPI1992796759assigned 11/01/2005
33bProvider typeMagnetic Resonance Imaging (MRI) Internal Medicine Physician
28Total paid$3.40M
24GClaims318,520
24DCodes billed65
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,021 | $387K | |
| 2019 | 64,519 | $379K | |
| 2020 | 49,523 | $538K | |
| 2021 | 43,201 | $285K | |
| 2022 | 49,211 | $788K | |
| 2023 | 58,657 | $649K | |
| 2024incomplete | 33,388 | $376K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 31,996 | 27,145 | $707K |
| J9271 | Injection, pembrolizumab, 1 mg | 18% | 208 | 169 | $608K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 13% | 42,387 | 26,761 | $426K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 6.5% | 24,060 | 12,155 | $221K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 6.3% | 23,416 | 13,250 | $214K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.5% | 23,070 | 22,149 | $152K |
| 96367 | 4.4% | 17,224 | 8,244 | $150K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 4.3% | 16,333 | 7,705 | $146K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.8% | 7,975 | 4,433 | $131K |
| 99000 | 2.6% | 25,333 | 17,501 | $89K | |
| 36415 | Collection of venous blood by venipuncture | 2.3% | 8,594 | 6,050 | $77K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2.2% | 15,184 | 7,393 | $73K |
53 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 11,098 | $71K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 1.7% | 10,220 | $59K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 5,935 | $38K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,420 | $31K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,702 | $29K |
| 96415 | <1% | 3,518 | $28K | |
| 96368 | <1% | 9,074 | $23K | |
| 96417 | <1% | 3,948 | $22K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 701 | $21K |
| 1126F | <1% | 5,262 | $15K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,061 | $11K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 341 | $11K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 782 | $7K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 899 | $6K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 486 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,888 | $4K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 379 | $4K |
| 99205 | Prolong outpt/office vis | <1% | 77 | $3K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 20 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,133 | $2K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 79 | $2K |
| 3074F | <1% | 1,746 | $2K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 364 | $2K |
| 36591 | <1% | 2,048 | $1K | |
| 3080F | <1% | 1,947 | $1K | |
| 96416 | <1% | 339 | $1K | |
| 96411 | <1% | 773 | $805.75 | |
| 3078F | <1% | 1,595 | $726.01 | |
| 3077F | <1% | 2,252 | $687.37 | |
| 96402 | <1% | 282 | $641.16 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 153 | $531.79 |
| 3079F | <1% | 743 | $431.08 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 172 | $375.26 |
| 96523 | <1% | 93 | $373.97 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 130 | $354.68 |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 80 | $310.52 |
| 1159F | <1% | 439 | $305.08 | |
| 1125F | <1% | 172 | $285.67 | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 243 | $253.83 |
| S0028 | Injection, famotidine, 20 mg | <1% | 551 | $208.36 |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 44 | $164.09 |
| 3075F | <1% | 280 | $147.01 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 71 | $133.75 |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 376 | $102.00 |
| 99195 | <1% | 29 | $31.61 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 405 | $24.70 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 106 | $23.15 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21 | $2.73 |
| J3490 | Unclassified drugs | <1% | 24 | $1.75 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 82 | $0.00 |
| J9206 | Injection, irinotecan, 20 mg | 0% | 41 | $0.00 |
| 2010F | 0% | 97 | $0.00 | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALCHANDANI, RAM (PRESIDENT)